PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd (Otsuka) and H. Lundbeck A/S (Lundbeck) published results from research demonstrating that an investigational ...

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka America Pharmaceutical, Inc. (OAPI) and Lundbeck today announced that the U.S. Food and Drug Administration (FDA) has expanded the label of ...

Abilify Maintena, an atypical antipsychotic, is currently available as an intramuscular depot formulation of aripiprazole for the treatment of schizophrenia. It is a sterile lyophilized powder that, ...

TOKYO — The Food and Drug Administration has approved a once-monthly treatment for schizophrenia. Otsuka Pharmaceutical and H. Lundbeck announced the FDA approval of Abilify Maintena (aripiprazole) ...

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Lundbeck announced today that the U.S. Food and Drug Administration (FDA) ...

According to the National Institute on Minority Health and Health Disparities (NIMHD), less than half of all Americans who have a mental disorder get proper treatment, and less than 10% of patients ...

ABILIFY MAINTENA (aripiprazole) 300mg and 400mg ext-rel injectable suspension Lundbeck and Otsuka announced that the Food and Drug Administration (FDA) has expanded the label of Abilify Maintena ...

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Lundbeck Pharmaceuticals LLC (Lundbeck) announce the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Abilify ...

Please provide your email address to receive an email when new articles are posted on . Otsuka Pharmaceutical, Inc. and Lundbeck recently announced the FDA expanded the label of Abilify Maintena for ...

Aripiprazole maintena requires a two-week oral medication overlap; aripiprazole lauroxil requires a three-week oral overlap. Tolerability of aripiprazole among patients with bipolar disorder is ...

Erin Crown, PA-C, CAQ-Psychiatry is a paid consultant of ®2024 Otsuka America Pharmaceutical, Inc. and Lundbeck, manufacturers of ABILIFY ASIMTUFII ® (aripiprazole) and ABILIFY MAINTENA ® ...

Approval provides patients with schizophrenia the ability to access the efficacy and safety profile of oral aripiprazole in a once-monthly formulation. Relapse prevention is an important consideration ...